The estimated Net Worth of Morgan R Brown is at least $1.32 Milion dollars as of 15 December 2020. Mr Brown owns over 28,125 units of Lipocine Inc stock worth over $795,529 and over the last 11 years he sold LPCN stock worth over $0. In addition, he makes $526,850 as Exec. VP, CFO a Principal Accounting Officer & Corp. Sec. at Lipocine Inc.
Sign up
Mr MBA LPCN stock SEC Form 4 insiders trading
Mr has made over 4 trades of the Lipocine Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 28,125 units of LPCN stock worth $110,250 on 15 December 2020.
The largest trade he's ever made was exercising 128,254 units of Lipocine Inc stock on 4 December 2020 worth over $502,756. On average, Mr trades about 10,631 units every 52 days since 2013. As of 15 December 2020 he still owns at least 202,941 units of Lipocine Inc stock.
You can see the complete history of Mr Brown stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Morgan R. Brown CPA, M.B.A., CPA, MBA biography
Morgan R. Brown CPA, M.B.A., CPA, MBA is the Exec. VP, CFO, Principal Accounting Officer & Corp. Sec. at Lipocine Inc.
What is the salary of Mr MBA?
As the Exec. VP, CFO a Principal Accounting Officer & Corp. Sec. of Lipocine Inc, the total compensation of Mr MBA at Lipocine Inc is $526,850. There are 3 executives at Lipocine Inc getting paid more, with Mahesh Patel having the highest compensation of $966,397.
How old is Mr MBA?
Mr MBA is 52, he's been the Exec. VP, CFO a Principal Accounting Officer & Corp. Sec. of Lipocine Inc since . There are 9 older and 3 younger executives at Lipocine Inc. The oldest executive at Lipocine Inc is Dr. Mahesh V. Patel Ph.D., 64, who is the Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO.
What's Mr MBA's mailing address?
Morgan's mailing address filed with the SEC is 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121.
Insiders trading at Lipocine Inc
Over the last 11 years, insiders at Lipocine Inc have traded over $9,045 worth of Lipocine Inc stock and bought 890,945 units worth $696,169 . The most active insiders traders include Mahesh V. Patel, John W. Higuchi a Morgan R Brown. On average, Lipocine Inc executives and independent directors trade stock every 72 days with the average trade being worth of $148,846. The most recent stock trade was executed by Mahesh V. Patel on 25 May 2023, trading 8,706 units of LPCN stock currently worth $43,791.
What does Lipocine Inc do?
lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.
What does Lipocine Inc's logo look like?
Complete history of Mr Brown stock trades at Lipocine Inc a Clene Nanomedicine
Lipocine Inc executives and stock owners
Lipocine Inc executives and other stock owners filed with the SEC include:
-
Mahesh Patel,
Chairman of the Board, President, Chief Executive Officer -
Dr. Mahesh V. Patel Ph.D.,
Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO -
Dr. Mahesh V. Patel,
Co-Founder, Chairman, Pres & CEO -
Morgan R. Brown CPA, CPA, M.B.A., MBA,
Corp. Sec. -
Morgan R. Brown CPA, M.B.A., CPA, MBA,
Exec. VP, CFO, Principal Accounting Officer & Corp. Sec. -
Morgan Brown,
Chief Financial Officer, Executive Vice President -
Nachiappan Chidambaram Ph.D.,
VP of Product Devel. -
John Higuchi,
Non-Executive Director -
Richard Ono,
Director -
Jeffrey Fink,
Director -
Stephen Hill,
Lead Independent Director -
Krista Fogarty,
Principal Accounting Officer & Corp. Controller -
Dr. Anthony DelConte M.D., M. D.,
Chief Medical Director -
Logan Morse,
VP of Sales, Marketing & Operations -
Jyrki Mattila,
Chief Business Officer -
Gregory Brooks Bass,
EVP and Chief Commercial Offic -
Srinivasan Venkateshwaran,
CTO and VP RandD -
Gerald T Simmons,
VP Corp Business Development -
Robert K. Merrell,
VP Finance -
Jill M. Jene,
Director -
Spyros Papapetropoulos,
Director -
Krista Fogarty,
Principal Accounting Officer -
George Nomikos,
Chief Medical Officer